Firebrick Pharma Eyes Global Expansion for Nasodine Nasal Spray; Shares Up 8%

MT Newswires Live09-25

Firebrick Pharma (ASX:FRE) intends to get its Nasodine nasal spray approved in all markets over the long term to receive royalties and license fees through its partners, according to a Wednesday filing with the Australian bourse.

In its investor update, Firebrick Pharma said it expects a decision on its application for Nasodine to be marketed as a nasal antiseptic in Europe in 2025. Once approved, the company plans to lodge its application in New Zealand and South Africa.

Nasodine is being marketed as a nasal cleanser in the US, where the company plans to pursue pharmacy distribution.

In the Philippines, the product is expected to be launched as a nasal antiseptic in 2025.

The pharmaceutical company's shares were up nearly 8% in recent Wednesday trade.

Price (AUD): $0.06, Change: $+0.004, Percent Change: +7.69%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470408064?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-25 11:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470408064","market":"nz","top_or_hot":-1,"title":"Firebrick Pharma Eyes Global Expansion for Nasodine Nasal Spray; Shares Up 8%","media":"MT Newswires Live","content":"<html><body><p> Firebrick Pharma (ASX:FRE) intends to get its Nasodine nasal spray approved in all markets over the long term to receive royalties and license fees through its partners, according to a Wednesday filing with the Australian bourse.</p><p>In its investor update, Firebrick Pharma said it expects a decision on its application for Nasodine to be marketed as a nasal antiseptic in Europe in 2025. Once approved, the company plans to lodge its application in New Zealand and South Africa.</p><p>Nasodine is being marketed as a nasal cleanser in the US, where the company plans to pursue pharmacy distribution.</p><p>In the Philippines, the product is expected to be launched as a nasal antiseptic in 2025.</p><p>The pharmaceutical company's shares were up nearly 8% in recent Wednesday trade.</p><p>Price (AUD): $0.06, Change: $+0.004, Percent Change: +7.69%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Firebrick Pharma Eyes Global Expansion for Nasodine Nasal Spray; Shares Up 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirebrick Pharma Eyes Global Expansion for Nasodine Nasal Spray; Shares Up 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-25 11:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Firebrick Pharma (ASX:FRE) intends to get its Nasodine nasal spray approved in all markets over the long term to receive royalties and license fees through its partners, according to a Wednesday ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2470408064","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470408064","pubTimestamp":1727235693,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Firebrick Pharma  intends to get its Nasodine nasal spray approved in all markets over the long term to receive royalties and license fees through its partners, according to a Wednesday filing with the Australian bourse.In its investor update, Firebrick Pharma said it expects a decision on its application for Nasodine to be marketed as a nasal antiseptic in Europe in 2025. Once approved, the company plans to lodge its application in New Zealand and South Africa.Nasodine is being marketed as a nasal cleanser in the US, where the company plans to pursue pharmacy distribution.In the Philippines, the product is expected to be launched as a nasal antiseptic in 2025.The pharmaceutical company's shares were up nearly 8% in recent Wednesday trade.Price : $0.06, Change: $+0.004, Percent Change: +7.69%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","FRE.AU":"FIREBRICK PHARMA LTD","AUD":"Audacy Inc.","BK4125":"广播"},"translate_title":"Firebrick Pharma着眼于Nasodine鼻喷雾剂的全球扩张；股价上涨8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"FRE.AU":0.9},"content_text":"Firebrick Pharma (ASX:FRE) intends to get its Nasodine nasal spray approved in all markets over the long term to receive royalties and license fees through its partners, according to a Wednesday filing with the Australian bourse.In its investor update, Firebrick Pharma said it expects a decision on its application for Nasodine to be marketed as a nasal antiseptic in Europe in 2025. Once approved, the company plans to lodge its application in New Zealand and South Africa.Nasodine is being marketed as a nasal cleanser in the US, where the company plans to pursue pharmacy distribution.In the Philippines, the product is expected to be launched as a nasal antiseptic in 2025.The pharmaceutical company's shares were up nearly 8% in recent Wednesday trade.Price (AUD): $0.06, Change: $+0.004, Percent Change: +7.69%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470408064"}